Aichler, M., & Ott, K. (2014). Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. OncoTarget, 5(16), . https://doi.org/10.18632/oncotarget.2268
Chicago-Zitierstil (17. Ausg.)Aichler, Michaela, und Katja Ott. "Epidermal Growth Factor Receptor (EGFR) Is an Independent Adverse Prognostic Factor in Esophageal Adenocarcinoma Patients Treated with Cisplatin-based Neoadjuvant Chemotherapy." OncoTarget 5, no. 16 (2014). https://doi.org/10.18632/oncotarget.2268.
MLA-Zitierstil (9. Ausg.)Aichler, Michaela, und Katja Ott. "Epidermal Growth Factor Receptor (EGFR) Is an Independent Adverse Prognostic Factor in Esophageal Adenocarcinoma Patients Treated with Cisplatin-based Neoadjuvant Chemotherapy." OncoTarget, vol. 5, no. 16, 2014, https://doi.org/10.18632/oncotarget.2268.